Sector News

Novartis to acquire AveXis for $8.7 billion in cash

April 9, 2018
Life sciences

Novartis AG said Monday that it has entered into an agreement to acquire clinical-stage gene therapy group AveXis Inc. for $8.7 billion in cash, or $218 per share.

Novartis, a Swiss-based pharmaceutical group, said the deal has been unanimously approved by the boards of both companies.

In acquiring AveXis, Novartis said it hopes to expand its role as a leader in gene therapy and neuroscience. Assuming completion by the middle of this year, the Swiss group said the deal would be slightly negative to its core operating income in 2018 and 2019, mainly due to research and development investments. But by 2020, Novartis expects the acquisition to “strongly contribute” to core operating income and earnings per share owing to an expected boost in sales.

By Barbara Kollmeyer

Source: MarketWatch

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.